What's fishy about protamine? Clinical use, adverse reactions, and potential alternatives.

dc.contributor.author

Levy, Jerrold H

dc.contributor.author

Ghadimi, Kamrouz

dc.contributor.author

Kizhakkedathu, Jayachandran N

dc.contributor.author

Iba, Toshiaki

dc.date.accessioned

2024-01-10T17:07:22Z

dc.date.available

2024-01-10T17:07:22Z

dc.date.issued

2023-07

dc.description.abstract

Protamine, a highly basic protein isolated from salmon sperm, is the only clinically available agent to reverse the anticoagulation of unfractionated heparin. Following intravenous administration, protamine binds to heparin in a nonspecific electrostatic interaction to reverse its anticoagulant effects. In clinical use, protamine is routinely administered to reverse high-dose heparin anticoagulation in cardiovascular procedures, including cardiac surgery with cardiopulmonary bypass. Despite the lack of supportive evidence regarding protamine's effectiveness to reverse low-molecular-weight heparin, it is recommended in guidelines with low-quality evidence. Different dosing strategies have been reported for reversing heparin in cardiac surgical patients based on empiric dosing, pharmacokinetics, or point-of-care measurements of heparin levels. Protamine administration is associated with a spectrum of adverse reactions that range from vasodilation to life-threatening cardiopulmonary dysfunction and shock. The life-threatening responses appear to be hypersensitivity reactions due to immunoglobulin E and/or immunoglobulin G antibodies. However, protamine and heparin-protamine complexes can activate complement inflammatory pathways and inhibit other coagulation factors. Although alternative agents for reversing heparin are not currently available for clinical use, additional research continues evaluating novel therapeutic approaches.

dc.identifier

S1538-7836(23)00319-7

dc.identifier.issn

1538-7933

dc.identifier.issn

1538-7836

dc.identifier.uri

https://hdl.handle.net/10161/29711

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Journal of thrombosis and haemostasis : JTH

dc.relation.isversionof

10.1016/j.jtha.2023.04.005

dc.rights.uri

https://creativecommons.org/licenses/by-nc/4.0

dc.subject

Semen

dc.subject

Humans

dc.subject

Heparin

dc.subject

Protamines

dc.subject

Anticoagulants

dc.subject

Heparin Antagonists

dc.subject

Cardiopulmonary Bypass

dc.subject

Male

dc.title

What's fishy about protamine? Clinical use, adverse reactions, and potential alternatives.

dc.type

Journal article

duke.contributor.orcid

Levy, Jerrold H|0000-0003-3766-4962

duke.contributor.orcid

Ghadimi, Kamrouz|0000-0002-9287-7541

pubs.begin-page

1714

pubs.end-page

1723

pubs.issue

7

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Anesthesiology

pubs.organisational-group

Anesthesiology, Cardiothoracic

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Cardiovascular and Thoracic Surgery

pubs.publication-status

Published

pubs.volume

21

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Levy_JTH_protamine.pdf
Size:
384.82 KB
Format:
Adobe Portable Document Format